Articles tagged "Heart transplant patients"

2022 American Transplant Congress
Association Between Time in Therapeutic Range for Warfarin and Time in Therapeutic Range for Calcineurin Inhibitors in Patients That Received Left Ventricular Assist Devices as Bridge to Transplant
G. Flajc¹, X. Huang², C. Minard², M. Manson¹, Z. Truman¹
¹Baylor St. Luke's Medical Center, Houston, TX, ²Baylor College of Medicine, Houston, TX
*Purpose: Medication nonadherence is a leading cause of avoidable graft failure post-transplant. The relationship between medication adherence in patients with left ventricular assist devices (LVADs)…
2022 American Transplant Congress
Identifying Predictors of Pediatric Heart Only versus Combined Heart-Liver Transplantation
K. Zhang, S. Chen, A. Syed, A. Gallo, C. Esquivel, C. Bonham, S. Hollander, M. Ma, J. Han, N. Ebel
Stanford University, Stanford, CA
*Purpose: A standardized protocol to identify which patients with Fontan failure require combined heart liver transplant (cHLT) versus isolated heart transplant (HT) has not yet…
2022 American Transplant Congress
Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)
J. Lee, T. Sam, J. Van Zyl, S. Mckean, L. Fuller, N. Wilson, A. Dao, R. Gottlieb, S. Hall, R. Patel
Baylor University Medical Center, Dallas, TX
*Purpose: AMR in HTR portends poor clinical outcomes. Reported mortality range between 20-50%, with higher rates reported for late AMR occurring at least 1 year…
2022 American Transplant Congress
The Use of Donor-Derived Cell-Free DNA in Female and Male Heart Transplant Recipients: A Sex-Specific Analysis of the Surveillance Heartcare Outcomes Registry
E. M. DeFilippis¹, Y. Fu², R. Burke², M. Deng³, M. Kamath⁴, L. Lourenco Jenkins², A. R. Vest⁵
¹Columbia University Irving Medical Center, New York, NY, ²CareDx, Brisbane, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁵Tufts Medical Center, Boston, MA
*Purpose: To investigate sex-specific donor-derived cell-free DNA AlloSure (AS) levels during allograft quiescence and rejection after heart transplantation.*Methods: Sex-stratified data were obtained from the Surveillance…
2022 American Transplant Congress
Characterization Of Local Antibody Responses In Human Cardiac Allograft Vasculopathy
S. B. See¹, L. J. Stanton¹, P. Roy¹, S. Mashiko¹, E. R. Vasilescu², C. C. Marboe², M. Szabolcs², M. V. Habal³, M. Farr³, S. Restaino³, Y. Naka⁴, D. M. Mancini⁵, J. C. Madsen⁶, R. G. King⁷, E. P. Kransdorf⁸, E. Zorn¹
¹CCTI, Columbia University Irving Medical Center, New York, NY, ²Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, ³Medicine, Columbia University Irving Medical Center, New York, NY, ⁴Surgery, Columbia University Irving Medical Center, New York, NY, ⁵Cardiology, Icahn School of Medicine, New York, NY, ⁶CTS, Massachusetts General Hospital, Boston, MA, ⁷Microbiology, University of Alabama, Birmingham, AL, ⁸Cedars-Sinai Heart Institute, Los Angeles, CA
*Purpose: Cardiac allograft vasculopathy (CAV) is the leading cause of heart graft recipient mortality after five years post-transplant. A major hurdle to improving outcomes is…
2022 American Transplant Congress
Increase in Exception and Extension Requests for Higher-Urgency Patients Under the New Heart Allocation Policy
J. R. Golbus¹, Y. Ahn², B. K. Nallamothu¹, M. N. Walsh³, D. Zaun², A. Israni², M. Colvin¹
¹University of Michigan, Ann Arbor, MI, ²Hennepin Healthcare Research Institute, Minneapolis, MN, ³Ascension St. Vincent Heart Center, Carmel, IN
*Purpose: In October 2018, a new heart allocation policy was introduced that expanded the number of listing statuses and established a national review board, abolishing…
2022 American Transplant Congress
Safety of Stimulant Use in Heart Transplant Recipients
K. Callaghan¹, M. Norris¹, C. Sammons¹, T. Fallah¹, H. Eldabbas¹, X. Liu¹, T. Wang²
¹Pharmacy, Hospital of the Univ of Pennsylvania, Philadelphia, PA, ²Cardiovascular Medicine, Hospital of the Univ of Pennsylvania, Philadelphia, PA
*Purpose: FDA-approved prescribed stimulants are purported to increase risk of cardiovascular (CV) adverse events, particularly arrhythmias and sudden cardiac death. Debate exists regarding the safety…
2022 American Transplant Congress
A Single Center Experience of Simultaneous Heart-Kidney Transplantation
A. Samra¹, A. Mattoo²
¹Nephrology, New York University Langone Transplant Institute, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Currently there are no UNOS guidelines regarding the selection criteria required for simultaneous heart-kidney transplant recipients (SHKT). As of 2018 our center has begun…
2022 American Transplant Congress
Pregnancy After Heart Transplant Does Not Negatively Impact Long Term Patient Survival
M. J. Moritz¹, D. Lee², C. Madu², S. Hossain³, L. A. Coscia⁴, S. Rao⁵, S. Constantinescu⁶
¹Surgery, Lehigh Valley Health Network, Allentown, PA, ²Cardiovascular Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, ³Data Analytics, University of South Florida, Muma College of Business, Tampa, FL, ⁴Transplant Pregnancy Registry International, Philadelphia, PA, ⁵Nephrology, University of Virginia Health System, Charlottesville, VA, ⁶Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
*Purpose: To evaluate the impact of pregnancy on patient survival in heart transplant recipients (HTRs), we linked the Transplant Pregnancy Registry International (TPRI) dataset with…
2022 American Transplant Congress
Direct Oral Anticoagulants versus Warfarin in Adult Heart Transplant Recipients
L. Shitanishi, A. Fan, T. Khuu, R. Ardehali
University of California Los Angeles, Los Angeles, CA
*Purpose: Direct oral anticoagulants (DOACs) have recently transformed the field of anticoagulation, offering more predictable pharmacokinetic and pharmacodynamic characteristics when compared to traditional warfarin therapy.…